PR & Com
Resources

Scroll to explore

Domain’s Resources

Our most up-to-date material only a click away

A pan group III mGluR PAM candidate ready to enter pre-IND studies

By targeting not only mGluR4 but also mGluR7 and 8, and by exhibiting an improved oral PK profile, DT095435 is positioned as a second generation compound that should succeed in reaching clinical efficacy where Foliglurax narrowly failed.

Download file

In order to download this file, please fill the form bellow.

A reliable real time pharmacological platform dedicated to the study of ICP co-receptors

This poster presents bioSens-All®️, a powerful and versatile pharmacological platform which is highly adaptable for hot topic targets such as Immune Checkpoint targets (Inhibitory & Stimulatory Immune Checkpoints).

Download file

In order to download this file, please fill the form bellow.

Use of novel ebBRET biosensors for comprehensive signaling profiling of 100 therapeutically relevant human GPCRs

Here, we describe a novel suite of enhanced bystander bioluminescence resonance energy transfer (ebBRET)-based biosensors that were used to define the signaling profiles of 100 therapeutically relevant human GPCRs in response to endogenous (or prototypical) ligands.

Download file

In order to download this file, please fill the form bellow.

A high value pharmacological platform dedicated to the real time study of Stimulatory immune checkpoint signaling pathways

We present here several innovative BRET assays dedicated to inhibitory and stimulatory ICPs (PD-1, CTLA-4, 4-1BB), and developed by us.
The ICP platform set up here shows good accuracy & robustness and represents a solid & reliable technology for ICP dedicated drug discovery.

Download file

In order to download this file, please fill the form bellow.

A pharmacological platform for the real time study of ICP signaling pathways

This poster presents the last generation of our proprietary platform bioSens-All®️ which is dedicated to the identification and characterization of immune checkpoint inhibitors.

Download file

In order to download this file, please fill the form bellow.

DT095597 a New NPFFR1 Antagonist Devoid of Addictive Properties to Fight Opioid Crisis

This poster presents the characterization of a proprietary NPFF receptor antagonist as a game-changer and a promising therapeutic strategy to fight the current opioid crisis.

Download file

In order to download this file, please fill the form bellow.

Decrypting EGFR signaling with BRET biosensors : A novel approach to study RTK mutations and the effects of inhibitors

This poster illustrates a valuable BRET-based platform used to characterize RTK candidates regarding constitutive activity, real-time kinetics or impact of RTK mutations on signalling pathways.

Download file
“GPCR-ome” modulation upon PD1 / PDL1 axis blockade

co-authored with Explicyte, Bordeaux, France & Institut Bergonié, Bordeaux, France, this poster discloses an in-depth GPCR expression analysis from tumor microenvironment to dissect out mechanisms of resistance to immune checkpoint inhibitors.

Download file
DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties

This poster presents the complete characterization of Domain drug candidate benchmarked to EP4 antagonist molecules currently in the clinic and demonstrating a best-in-class potential.

Download file
DT095435: A novel “pan” group III metabotropic glutamate receptor positive allosteric modulator for Parkinson’s disease

This poster presents the profiling of DT095435, our pan group III mGluR PAM development candidate, as a potential new anti-dyskinetic treatment for Parkinson's disease.

Download file

In order to download this file, please fill the form bellow.

Creation of a large-spectrum GPCR biosensor for functional in vitro safety and systems pharmacology analysis

This study served as a validation of the utility of the Gz/G15 large-spectrum biosensor for safety and systems pharmacology profiling. Moreover, our results support the use of this cell-based functional assay in high throughput receptor deorphanization and functional screening programs.

Download file
GPCRs in oncology and immuno-oncology : The IRIC's virtual symposium 2021 [VIDEO]

Chaired by IRIC's CEO Michel Bouvier, this symposium will showcase some of the latest discoveries & techniques leveraging the potential of GPCRs in oncology and immuno-oncology.
Leading experts will share findings from world-class academic & private research on GPCRs in those crucial fields.

Download file